Internet Pioneer In...
Health Care: Drugs
Amgen Inc (AMGN: NASDAQ)
$67.75 -1.77 | -2.55%
06/01/12 - 04:00 PM ET
TheStreet Ratings Grade for AMGN
| Buy | Hold | Sell | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A+ | A | A- | B+ | B | B- | C+ | C | C- | D+ | D | D- | E+ | E | E- | F |
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions.
Analyst Ratings
| Historical Rec | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago |
|---|---|---|---|---|
| Stong Buy | 9 | 10 | 11 | 12 |
| Moderate Buy | 1 | 1 | 2 | 2 |
| Hold | 13 | 13 | 13 | 11 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 |
| Mean Rec. | 2.29 | 2.24 | 2.19 | 2.08 |
Portfolios with AMGN
- Portfolio NameUser Type
- UserLong Term Stock Picks by Co...
- Contributor5 Low Volatility Low PEG St...
- UserJimboPhi
- UserCorporate Communication cla...
- UserKAREL VON ZOETE
- UserMACHINE RECOMMENDATIONS
- UserMARIA DEL HUERTO
- ContributorHighest-Yielding Drug Stocks
- Contributor10 Health Care Stocks to Watch
- ContributorMost-Searched Stocks for th...
Latest AMGN Headlines from TheStreet
- Symmetry Projections
05.21.12 | 08:05 am - Amgen Inc (AMGN): Today's Featured Drugs Loser 05.18.12 | 05:05 pm
- 5 Cheap, Low-Risk Stocks to Buy 05.18.12 | 07:05 am
- Amgen Stock To Go Ex-dividend Monday (AMGN) 05.11.12 | 08:05 am
- Ex-Dividend Stocks: Target, ConEd 05.11.12 | 07:05 am
- Amgen Inc (AMGN): Today's Featured Drugs Winner 05.10.12 | 05:05 pm
- Amgen Inc (AMGN): Today's Featured Drugs Winner 05.02.12 | 04:05 pm
- Amgen Reaches New 52-Week High (AMGN) 04.25.12 | 01:04 pm
- Amgen Goes to Turkey, Loses Biotech Cred 04.25.12 | 09:04 am
- Amgen's CEO Discusses Q1 2012 Results - Earnings Call Transcript 04.24.12 | 10:04 pm
Press Releases for AMGN
- Amgen Announces Voting Results Of Annual Meeting Of Stockholders - PR Newswire 05.23.12 | 05:05 pm
- Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate Of Complete Response In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia - PR Newswire 05.16.12 | 06:05 pm
- Analysis Of Rilotumumab (AMG 102) Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - PR Newswire 05.16.12 | 06:05 pm
- Amgen To Present At The Baird Growth Stock Conference - PR Newswire 05.04.12 | 04:05 pm
- Amgen To Present At The Deutsche Bank 37th Annual Healthcare Conference - PR Newswire 05.03.12 | 06:05 pm
- Amgen Receives Complete Response Letter From FDA For XGEVA® SBLA For Prevention Of Bone Metastases - PR Newswire 04.26.12 | 10:04 pm
- Amgen To Acquire Mustafa Nevzat, A Leading Privately Held Turkish Pharmaceutical Company - PR Newswire 04.25.12 | 02:04 am
- A Tribute To George Rathmann, Amgen's Founding CEO (1927-2012) - PR Newswire 04.23.12 | 10:04 pm
- Amgen To Acquire Privately Held KAI Pharmaceuticals - PR Newswire 04.10.12 | 08:04 am
- UCB And Amgen Initiate Sclerostin Antibody Phase 3 Program In Patients With Postmenopausal Osteoporosis - PR Newswire 04.04.12 | 01:04 am
Partner Headlines for AMGN
- Health Care SPDR In Focus Ahead Of Obamacare Decision - Benzinga 05.22.12 | 12:05 pm
- The Definitive Biotech ETF Guide (IBB, XBI, FBT) - Benzinga 05.21.12 | 01:05 pm
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- Amgen Beats but Maintains Outlook - Analyst Blog - Zacks 04.25.12 | 10:04 am
- Top Undervalued High Conviction Outperforming Picks From Eaton Vance's $47 Billion Q1 Filng - Seeking Alpha 04.20.12 | 10:04 pm
- Earnings Preview: Abbott Labs - Analyst Blog - Zacks 04.17.12 | 10:04 am
- The Zacks Analyst Blog Highlights: The Goldman Sachs Group, Lloyd's, Bank of America, JPMorgan Chase and Amgen - Press Releases - Zacks 04.12.12 | 09:04 am
- Market Roundup - Benzinga 04.10.12 | 01:04 pm
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Amgen, Abbott, Teva All Incredibly Undervalued Stocks - Seeking Alpha 04.06.12 | 07:04 am
